Osborn D A, Sinn J K
Cochrane Database Syst Rev. 2007 Oct 17(4):CD006475. doi: 10.1002/14651858.CD006475.pub2.
The composition of the intestinal microflora may be different in individuals with atopic eczema from those without this condition, and such differences may precede the development of eczema. Probiotics are live bacteria that colonize the gastrointestinal tract and provide a health benefit to the host. Probiotics added to infant feeds have the potential to prevent sensitisation of infants to dietary allergens.
To determine the effect of probiotics given to infants for the prevention of allergic disease or food hypersensitivity.
This included searches of the Cochrane Central Register of Controlled Trials (Issue 1, 2007), MEDLINE (1966 - February 2007), EMBASE, PREMEDLINE, abstracts of conference proceedings and citations of published articles, and expert informants.
Randomised and quasi-randomised controlled trials that compare the use of a probiotic to no probiotic; or the use a specific probiotic compared to a different probiotic; or a probiotic with added prebiotic to control.
Assessment of trial quality, data extraction and synthesis of data were performed using standard methods of the Cochrane Neonatal Review Group.
Twelve studies were eligible for inclusion. Allergic disease and / or food hypersensitivity outcomes were assessed by 6 studies enrolling 2080 infants, but outcomes for only 1549 infants were reported. Studies generally had adequate randomisation, allocation concealment and blinding of treatment. However, the findings of this review should be treated with caution due to excess losses in patient follow-up (17% to 61%). Meta-analysis of five studies reporting the outcomes of 1477 infants found a significant reduction in infant eczema (typical RR 0.82, 95% CI 0.70, 0.95). However, there was significant and substantial heterogeneity between studies. One study reported that the difference in eczema between groups persisted to 4 years age. When the analysis was restricted to studies reporting atopic eczema (confirmed by skin prick test or specific IgE), the findings were no longer significant (typical RR 0.80, 95% CI 0.62, 1.02). All studies reporting significant benefits used probiotic supplements containing L. rhamnosus and enrolled infants at high risk of allergy. No other benefits were reported for any other allergic disease or food hypersensitivity outcome.
AUTHORS' CONCLUSIONS: There is insufficient evidence to recommend the addition of probiotics to infant feeds for prevention of allergic disease or food hypersensitivity. Although there was a reduction in clinical eczema in infants, this effect was not consistent between studies and caution is advised in view of methodological concerns regarding included studies. Further studies are required to determine whether the findings are reproducible.
特应性皮炎患者的肠道微生物群组成可能与非特应性皮炎患者不同,且这些差异可能在湿疹发生之前就已存在。益生菌是定殖于胃肠道并对宿主有益健康的活细菌。添加到婴儿食品中的益生菌有可能预防婴儿对食物过敏原的致敏。
确定给予婴儿益生菌对预防过敏性疾病或食物过敏的效果。
检索了Cochrane对照试验中央注册库(2007年第1期)、MEDLINE(1966年至2007年2月)、EMBASE、PREMEDLINE、会议论文摘要和已发表文章的引用文献,并咨询了专家。
比较使用益生菌与不使用益生菌;或使用特定益生菌与使用不同益生菌;或使用添加益生元的益生菌与对照的随机和半随机对照试验。
采用Cochrane新生儿综述组的标准方法进行试验质量评估、数据提取和数据综合。
12项研究符合纳入标准。6项研究纳入了2080名婴儿,评估了过敏性疾病和/或食物过敏结局,但仅报告了1549名婴儿的结局。研究一般具有充分的随机化、分配隐藏和治疗盲法。然而,由于患者随访中的大量失访(17%至61%),本综述的结果应谨慎对待。对5项报告了1477名婴儿结局的研究进行的荟萃分析发现,婴儿湿疹显著减少(典型相对危险度0.82,95%可信区间0.70,0.95)。然而,各研究之间存在显著且实质性的异质性。一项研究报告称,两组之间湿疹的差异持续到4岁。当分析仅限于报告特应性皮炎(经皮肤点刺试验或特异性IgE证实)的研究时,结果不再显著(典型相对危险度0.80,95%可信区间0.62,1.02)。所有报告有显著益处的研究都使用了含鼠李糖乳杆菌的益生菌补充剂,并纳入了过敏高风险婴儿。未报告对任何其他过敏性疾病或食物过敏结局有其他益处。
没有足够的证据推荐在婴儿食品中添加益生菌以预防过敏性疾病或食物过敏。尽管婴儿临床湿疹有所减少,但各研究结果不一致,鉴于纳入研究的方法学问题,建议谨慎对待。需要进一步研究以确定这些结果是否可重复。